Publications
Original Article
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature
T Cell Function & Therapy
2007
Authors:
Inokuma M, delaRosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang MX, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML and Maecker HT
Journal:
The Journal of Immunology
Volume:
179(4)
Page:
2627-33
Pubmed:
Original Article
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming
T Cell Function & Therapy
2007
Authors:
Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML
Journal:
Clinical Cancer Research
Volume:
13(6)
Page:
1883-91
Pubmed:
Original Article
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response
T Cell Function & Therapy
2007
Authors:
Wang LX, Shu S, Disis ML and Plautz GE
Journal:
Blood
Volume:
109(11)
Page:
4865-76
Pubmed:
Original Article
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers
Cancer Vaccines
2007
Authors:
Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K and Disis ML
Journal:
Clinical Immunology
Volume:
125(3)
Page:
275-80
Pubmed:
Original Article
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors
Measuring Human Immunity
2007
Authors:
Ghanekar SA, Bhatia S, Ruitenberg JJ, delaRosa C, Disis ML, Maino VC, Maeker HT and Waters CA
Journal:
Journal of Immune Based Therapies and Vaccines
Volume:
5
Page:
7
Pubmed:
Original Article
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens
Tumor Microenvironment
2006
Authors:
Lu H, Knutson KL, Gad E, Disis ML
Journal:
Cancer Research
Volume:
66(19)
Page:
9754-61
Pubmed:
Original Article
Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1
Cancer Vaccines
2006
Authors:
Wang W, Epler J, Salazar LG, and Riddell SR
Journal:
Cancer Research
Volume:
66(13)
Page:
6826-33
Pubmed:
Original Article
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"
Tumor Microenvironment
2006
Authors:
Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR and Kazim AL
Journal:
Breast Cancer Research and Treatment
Volume:
96(3)
Page:
243
Pubmed:
Original Article
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice
Cancer Vaccines
2006
Authors:
Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, and Disis ML
Journal:
Journal of Immunology
Volume:
177(1)
Page:
84-91
Pubmed:
Original Article
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain
General Immune Research
2006
Authors:
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, and Ostrand-Rosenberg S
Journal:
Cancer Research
Volume:
66(2)
Page:
1147-54
Pubmed: